Piper Sandler Reiterates Overweight on Mesoblast, Raises Price Target to $39

Benzinga Newsdesk www.benzinga.com Positive 59.7%

Neg 0% Neu 0% Pos 59.7%

Piper Sandler analyst Edward Tenthoff reiterates Mesoblast (NASDAQ:MESO) with a Overweight and raises the price target from $35 to $39.